Literature DB >> 14977039

Do nonprofit HMOs eliminate racial disparities in cardiac care?

Lenahan O'Connell1, Samuel L Brown.   

Abstract

African-Americans have far less access to treatment for heart disease than similar white Americans. In this article, we explore the sector difference theory hypothesis that treatment provided by a nonprofit Medicaid managed care plan can reduce or even eliminate the race gap. Specifically, we compare the treatment offered to patients in for-profit Medicaid managed care programs to the treatment offered to similar patients in nonprofit Medicaid managed care programs. Data are from the Maryland Health Services Cost Review Commission and cover all patients discharged from hospitals in Maryland during calendar year 1998 with principal diagnoses indicating diseases of the circulatory system (ICD-9-CM codes 390 through 459) or chest pain (ICD-9-CM codes 786.50 through 786.52 and code 786.59). African-Americans were significantly less likely to receive the three treatments of interest, even after controlling for principal diagnosis, blood pressure, co-morbidities, and age. In regard to African-American access to treatment, there were no significant differences between the sectors.

Entities:  

Mesh:

Year:  2003        PMID: 14977039

Source DB:  PubMed          Journal:  J Health Care Finance        ISSN: 1078-6767


  3 in total

1.  Reducing disparities downstream: prospects and challenges.

Authors:  Peter Franks; Kevin Fiscella
Journal:  J Gen Intern Med       Date:  2008-01-24       Impact factor: 5.128

2.  Physicians' perceptions of patients' social and behavioral characteristics and race disparities in treatment recommendations for men with coronary artery disease.

Authors:  Michelle van Ryn; Diana Burgess; Jennifer Malat; Joan Griffin
Journal:  Am J Public Health       Date:  2005-12-27       Impact factor: 9.308

3.  Racial and geographic variation in coronary heart disease mortality trends.

Authors:  Richard F Gillum; Alem Mehari; Bryan Curry; Thomas O Obisesan
Journal:  BMC Public Health       Date:  2012-06-06       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.